6029 Stock Overview
Provides support services for acupuncture, moxibustion, and orthopedic clinics in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Artra Group Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥147.00 |
| 52 Week High | JP¥328.00 |
| 52 Week Low | JP¥101.00 |
| Beta | 0.70 |
| 11 Month Change | -13.02% |
| 3 Month Change | -9.82% |
| 1 Year Change | -48.60% |
| 33 Year Change | -52.27% |
| 5 Year Change | -30.66% |
| Change since IPO | -56.47% |
Recent News & Updates
Shareholder Returns
| 6029 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | 5.8% | 2.7% | 3.2% |
| 1Y | -48.6% | 4.1% | 15.0% |
Return vs Industry: 6029 underperformed the JP Healthcare industry which returned 4.1% over the past year.
Return vs Market: 6029 underperformed the JP Market which returned 15% over the past year.
Price Volatility
| 6029 volatility | |
|---|---|
| 6029 Average Weekly Movement | 9.8% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in JP Market | 10.0% |
| 10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 6029's share price has been volatile over the past 3 months.
Volatility Over Time: 6029's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 156 | Hiroyuki Kyuse | www.artra-group.co.jp |
Artra Group Corporation provides support services for acupuncture, moxibustion, and orthopedic clinics in Japan. It operates through two segments, Acupuncture and Moxibustion Hospital Support Business, and Toy Sales Business. The company offers billing services; and HONEY-STYLE, a word-of-mouth / reservation system for acupuncture and moxibustion clinics.
Artra Group Corporation Fundamentals Summary
| 6029 fundamental statistics | |
|---|---|
| Market cap | JP¥1.52b |
| Earnings (TTM) | JP¥61.00m |
| Revenue (TTM) | JP¥4.44b |
24.7x
P/E Ratio0.3x
P/S RatioIs 6029 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6029 income statement (TTM) | |
|---|---|
| Revenue | JP¥4.44b |
| Cost of Revenue | JP¥3.01b |
| Gross Profit | JP¥1.43b |
| Other Expenses | JP¥1.37b |
| Earnings | JP¥61.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.94 |
| Gross Margin | 32.27% |
| Net Profit Margin | 1.37% |
| Debt/Equity Ratio | 96.3% |
How did 6029 perform over the long term?
See historical performance and comparison